Does potency predict clinical efficacy? Illustration through an antihistamine model
- 1 July 2002
- journal article
- review article
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 89 (1), 7-12
- https://doi.org/10.1016/s1081-1206(10)61904-7
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Skin concentrations of H1-receptor antagonistsJournal of Allergy and Clinical Immunology, 2001
- Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitisClinical and Experimental Allergy, 2000
- Functional neuroimaging of cognition impaired by a classical antihistamine, d‐chlorpheniramineBritish Journal of Pharmacology, 2000
- 1125 Function characterization of desloratadine and other antihistamines in a chinese hamster ovary (CHO) cell line that expresses the cloned human histamine H1 receptor and in human bronchial smooth muscle cells (HBSMC)Journal of Allergy and Clinical Immunology, 2000
- 1118 Preclinical efficacy and antiallergic profile of desloratadine, a selective and nonsedating histamine H1-receptor antagonistJournal of Allergy and Clinical Immunology, 2000
- Second-Generation AntihistaminesDrugs, 1999
- Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistaminesJournal of Allergy and Clinical Immunology, 1997
- Pharmacokinetics and pharmacodynamics of terfenadine and chlorpheniramine in the elderlyJournal of Allergy and Clinical Immunology, 1990
- Muscarinic Receptor SubtypesNew England Journal of Medicine, 1989
- The pharmacological profile of a specific, safe, effective and non-sedative anti-allergic, astemizoleInflammation Research, 1986